Illumina Inc.

ILMN-Q

NASDAQ:ILMN

319.58
7.42 (2.27%)
Illumina, Inc. is an American company incorporated in April 1998 that develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function.
More at Wikipedia

Analysis and Opinions about ILMN-Q

Signal
Opinion
Expert
TOP PICK
TOP PICK
September 12, 2019
They are a provider of sequencing solutions for genetic analysis. It is a really good entry level. It is a pretty volatile stock. Commercial genetic testing is going to explode and these guys are emphasizing consumables. (Analysts’ price target is $321.79)
Show full opinionHide full opinion
Illumina Inc. (ILMN-Q)
September 12, 2019
They are a provider of sequencing solutions for genetic analysis. It is a really good entry level. It is a pretty volatile stock. Commercial genetic testing is going to explode and these guys are emphasizing consumables. (Analysts’ price target is $321.79)
PAST TOP PICK
PAST TOP PICK
June 27, 2019
(A Top Pick Jul 18/18, Up 15%) They analyze genetic material. We are in the early stages of doing this for a whole host of applications. They are a generation ahead of competitors. This is a technology that is still relatively new.
Show full opinionHide full opinion
(A Top Pick Jul 18/18, Up 15%) They analyze genetic material. We are in the early stages of doing this for a whole host of applications. They are a generation ahead of competitors. This is a technology that is still relatively new.
TOP PICK
TOP PICK
June 5, 2019
The DNA revolution has recently started. DNA sequencing has come from the thousands of dollars to the hundreds making it ore retail. Fast growing US name. (Analysts’ price target is $345.93)
Show full opinionHide full opinion
The DNA revolution has recently started. DNA sequencing has come from the thousands of dollars to the hundreds making it ore retail. Fast growing US name. (Analysts’ price target is $345.93)
TOP PICK
TOP PICK
July 18, 2018

He is a big believer in disrupter companies in growth sectors. This is the only company in the world that can do high volume DNA sequencing. They already have a million customers and another million order backlog. There is no one else in this space. They sell equipment and the supplies to operate the equipment. Countries will have more DNA sequencing done to help new drug development. Yield 0%. (Analysts’ price target is $286.06)

Show full opinionHide full opinion

He is a big believer in disrupter companies in growth sectors. This is the only company in the world that can do high volume DNA sequencing. They already have a million customers and another million order backlog. There is no one else in this space. They sell equipment and the supplies to operate the equipment. Countries will have more DNA sequencing done to help new drug development. Yield 0%. (Analysts’ price target is $286.06)

COMMENT
COMMENT
October 28, 2013

Dominant player in gene sequencing business. Becoming more commercially available to clinics instead of just research labs. They are buying up some of their customers and going into competition with them. He is nervous of the valuation. It is at and beyond his expectations.

Show full opinionHide full opinion
Illumina Inc. (ILMN-Q)
October 28, 2013

Dominant player in gene sequencing business. Becoming more commercially available to clinics instead of just research labs. They are buying up some of their customers and going into competition with them. He is nervous of the valuation. It is at and beyond his expectations.

Showing 1 to 5 of 5 entries
  • «
  • 1
  • »